% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Klassen:124369,
      author       = {O. Klassen and M. Schmidt$^*$ and F.
                      Scharhag-Rosenberger$^*$ and C. M. Ulrich and A. Schneeweiss
                      and K. Potthoff and K. Steindorf$^*$ and J. Wiskemann$^*$},
      title        = {{M}uscle strength in breast cancer patients receiving
                      different treatment regimes.},
      journal      = {Journal of cachexia, sarcopenia and muscle},
      volume       = {8},
      number       = {2},
      issn         = {2190-5991},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DKFZ-2017-01248},
      pages        = {305 - 316},
      year         = {2017},
      note         = {Scharhag-Rosenberger, F, Sorkin, M not imported},
      abstract     = {Muscle dysfunction and sarcopenia have been associated with
                      poor performance status, an increased mortality risk, and
                      greater side effects in oncologic patients. However, little
                      is known about how performance is affected by cancer
                      therapy. We investigated muscle strength in breast cancer
                      patients in different adjuvant treatment settings and also
                      compared it with data from healthy individuals.Breast cancer
                      patients (N = 255) from two randomized controlled
                      exercise trials, staged 0-III and aged
                      54.4 ± 9.4 years, were categorized into four groups
                      according to their treatment status. In a cross-sectional
                      design, muscle function was assessed bilaterally by
                      isokinetic dynamometry (0°, 60°, 180°/s) as maximal
                      voluntary isometric contraction (MVIC) and maximal
                      isokinetic peak torque (MIPT) in shoulder rotators and knee
                      flexors and extensors. Additionally, muscular fatigue index
                      $(FI\%)$ and shoulder flexibility were evaluated. Healthy
                      women (N = 26), aged 53.3 ± 9.8 years, were
                      tested using the same method. Analysis of covariance was
                      used to estimate the impact of different cancer treatments
                      on skeletal muscle function with adjustment for various
                      clinical and socio-demographic factors.Consistently, lower
                      muscle strength was measured in shoulder and knee strength
                      in patients after chemotherapy. On average, patients had up
                      to $25\%$ lower strength in lower extremities and $12-16\%$
                      in upper extremities in MVIC and MIPT during cancer
                      treatment compared with healthy women. No substantial
                      difference between patient groups in shoulder strength, but
                      significantly lower shoulder flexibility in patients with
                      radical mastectomy was measured. Chemotherapy-treated
                      patients had consistently higher $FI\%.$ No serious adverse
                      events were reported.Breast cancer patients showed markedly
                      impaired muscle strength and joint dysfunctions before and
                      after anticancer treatment. The significant differences
                      between patients and healthy individuals underline the need
                      of exercise therapy as early as possible in order to prevent
                      or counteract the loss of muscle function after curative
                      surgery as well as the consequences of neo-/adjuvant
                      chemotherapy.},
      cin          = {G210},
      ddc          = {610},
      cid          = {I:(DE-He78)G210-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27896952},
      pmc          = {pmc:PMC5377413},
      doi          = {10.1002/jcsm.12165},
      url          = {https://inrepo02.dkfz.de/record/124369},
}